iBio, Inc. (IBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
IBIO POWR Grades
- Value is the dimension where IBIO ranks best; there it ranks ahead of 42.41% of US stocks.
- IBIO's strongest trending metric is Sentiment; it's been moving up over the last 106 days.
- IBIO's current lowest rank is in the Quality metric (where it is better than 0.62% of US stocks).
IBIO Stock Summary
- With a market capitalization of $6,471,923, IBIO INC has a greater market value than merely 1.63% of US stocks.
- The volatility of IBIO INC's share price is greater than that of 98.48% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IBIO comes in at 74.88% -- higher than that of 97.65% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to IBIO INC are EMKR, SCWX, PEAR, LAW, and DZSI.
- IBIO's SEC filings can be seen here. And to visit IBIO INC's official web site, go to www.ibioinc.com.
IBIO Valuation Summary
- In comparison to the median Healthcare stock, IBIO's price/earnings ratio is 100.44% lower, now standing at -0.1.
- Over the past 160 months, IBIO's price/earnings ratio has gone up 9.4.
Below are key valuation metrics over time for IBIO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
IBIO | 2023-01-20 | 2.9 | 0.1 | -0.1 | -0.3 |
IBIO | 2023-01-19 | 2.9 | 0.1 | -0.1 | -0.3 |
IBIO | 2023-01-18 | 2.9 | 0.1 | -0.1 | -0.3 |
IBIO | 2023-01-17 | 3.0 | 0.1 | -0.1 | -0.3 |
IBIO | 2023-01-13 | 3.5 | 0.2 | -0.1 | -0.3 |
IBIO | 2023-01-12 | 3.1 | 0.1 | -0.1 | -0.3 |
IBIO Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 339.39%.
- Its 4 year net income to common stockholders growth rate is now at -203.93%.
- Its 4 year revenue growth rate is now at 151.53%.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 2.172 | -42.092 | -59.516 |
2022-06-30 | 2.383 | -37.48 | -50.391 |
2022-03-31 | 2.813 | -33.203 | -33.286 |
2021-12-31 | 1.635 | -34.608 | -28.621 |
2021-09-30 | 2.172 | -32.341 | -24.873 |
2021-06-30 | 2.371 | -30.064 | -23.467 |
IBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
- COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.
The table below shows IBIO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.017 | 0.383 | -0.256 |
2021-03-31 | 0.024 | 0.836 | -0.331 |
2020-12-31 | 0.023 | 1.000 | -0.317 |
2020-09-30 | 0.027 | 1.000 | -0.273 |
2020-06-30 | 0.032 | 1.000 | -0.231 |
2020-03-31 | 0.036 | 1.000 | -0.271 |
IBIO Stock Price Chart Interactive Chart >
IBIO Price/Volume Stats
Current price | $0.74 | 52-week high | $16.51 |
Prev. close | $0.72 | 52-week low | $0.36 |
Day low | $0.70 | Volume | 188,100 |
Day high | $0.74 | Avg. volume | 891,006 |
50-day MA | $0.90 | Dividend yield | N/A |
200-day MA | $4.76 | Market Cap | 6.66M |
iBio, Inc. (IBIO) Company Bio
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.
Latest IBIO News From Around the Web
Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.
iBio Announces Closing of $3.5 Million Underwritten Public OfferingBRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock, at a combine |
7 Penny Stocks to Sell Before They Plunge in 2023These penny stocks to sell have been incredibly volatile this year and should be discarded from your portfolios heading into 2023 |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday! |
25 Penny Stocks to Sell Before They DieWondering which small-cap companies you should offload before 2023? |
iBio Announces Pricing of $3.5 Million Underwritten Public OfferingBRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,365,385 shares of common stock and Series B warrants to purchase up to 3,365,385 shares of common stock, at a combine |
IBIO Price Returns
1-mo | 64.81% |
3-mo | -64.76% |
6-mo | -87.25% |
1-year | -93.35% |
3-year | -87.87% |
5-year | -98.36% |
YTD | 66.52% |
2022 | -96.76% |
2021 | -47.71% |
2020 | 321.69% |
2019 | -66.80% |
2018 | -57.63% |
Continue Researching IBIO
Want to do more research on iBio Inc's stock and its price? Try the links below:iBio Inc (IBIO) Stock Price | Nasdaq
iBio Inc (IBIO) Stock Quote, History and News - Yahoo Finance
iBio Inc (IBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...